Expert Discusses Promise of CMB305 Immunotherapy Regimen in Sarcoma – Targeted Oncology
Targeted Oncology |
Expert Discusses Promise of CMB305 Immunotherapy Regimen in Sarcoma
Targeted Oncology CMB305, an immunotherapy regimen that generates and expands anti–NY-ESO-1 T cells, demonstrated a favorable survival rate compared with other approved agents for recurrent soft tissue sarcoma, according to results presented at the 2017 ASCO Annual … |
